Holen Sie sich die Stockscreener-App
1.69
0.00%
0.00
Vorhandelsmarkt:
1.71
0.02
+1.18%
Schlusskurs vom Vortag:
$1.69
Offen:
$1.73
24-Stunden-Volumen:
1.65M
Relative Volume:
1.33
Marktkapitalisierung:
$116.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-89.66M
KGV:
-0.6982
EPS:
-2.4205
Netto-Cashflow:
$-81.90M
1W Leistung:
+1.20%
1M Leistung:
-68.26%
6M Leistung:
-63.10%
1J Leistung:
+53.64%
1-Tages-Spanne:
$1.68
$1.80
1-Wochen-Bereich:
$1.57
$1.80
52-Wochen-Spanne:
$1.01
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Firmenname
Pepgen Inc
Sektor
Branche
Telefon
703-456-8000
Adresse
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.69 | 113.35M | 0 | -89.66M | -81.90M | -2.4205 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-09 | Eingeleitet | Guggenheim | Buy |
| 2024-12-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-07-31 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-21 | Eingeleitet | H.C. Wainwright | Buy |
Pepgen Inc Aktie (PEPG) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph
Biotech Firm PepGen Receives 'Moderate Buy' Rating from Analysts - National Today
PepGen: Modest FREEDOM2 Efficacy, Regulatory Overhang, and Competitive Pressures Underscore Sell Rating - TipRanks
Signal Recap: Should I set a stop loss on PepGen Inc2026 Pullback Review & Technical Confirmation Alerts - baoquankhu1.vn
PepGen crashes after mid-stage trial data for muscle disorder therapy - MSN
PepGen team joins Kansas City event to drive myotonic dystrophy research discussions - Traders Union
Rate Cut: Does PepGen Inc have declining or rising EPSAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
PepGen joins MyotonicStrong conference to present clinical progress - Traders Union
Top 3 Health Care Stocks Which Could Blast Off This Quarter - Benzinga
Retail Trends: Is PepGen Inc forming a breakout pattern2026 Chart Watch & Long Hold Capital Preservation Tips - baoquankhu1.vn
Published on: 2026-04-07 21:04:49 - baoquankhu1.vn
PEPG.O Technical Analysis & Stock Price Forecast - Intellectia AI
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
PEPG Technical Analysis & Stock Price Forecast - Intellectia AI
PepGen stock plunges 26% on FDA partial clinical hold - Investing.com
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway - National Today
Wedbush Maintains PepGen (PEPG) Outperform Recommendation - MSN
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Assay what? Eyes on Pepgen’s vim-sapping DM1 phase II - BioWorld MedTech
Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts - TipRanks
PEPG: FREEDOM2's 5 mg/kg cohort showed promising safety and efficacy, supporting dose escalation - TradingView — Track All Markets
MACD Signal: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEAR2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
PepGen Shares Fall After Data From Ongoing Phase 2 Study for Myotonic Dystrophy Type 1 Patients - MarketScreener
PepGen's 5 mg/kg Data Outlier: Is This a Prelude to a 10 mg/kg Comeback or Evidence of a Failed Strategy? - Bitget
PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief - Seeking Alpha
PepGen’s Stock Plummets Amid FDA Trial Hold and Market Reaction - StocksToTrade
PepGen (NASDAQ:PEPG) Price Target Lowered to $5.00 at Wedbush - MarketBeat
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease - BioSpace
PepGen Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
A Quick Look at Today's Ratings for PepGen(PEPG.US), With a Forecast Between $3 to $20 - news.futunn.com
Why PEPG, SGMO, PHR are among top premarket losers today - MSN
Wedbush Cuts Price Target on PepGen to $5 From $9, Keeps Outperform Rating - marketscreener.com
Why Is PepGen Stock Sinking Tuesday? - Benzinga
PepGen posts trial data for muscle disorder drug (PEPG:NASDAQ) - Seeking Alpha
PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT DataSlideshow (NASDAQ:PEPG) 2026-03-31 - Seeking Alpha
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data - BioSpace
PepGen reports ‘promising’ topline results from MAD cohort - TipRanks
PepGen stock tumbles 44% on disappointing trial results By Investing.com - Investing.com Canada
Movement Recap: Should I set a stop loss on PepGen Inc2026 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
PepGen Reports Early Phase 2 FREEDOM2-DM1 Topline Data - TipRanks
PepGen reports mixed results from DM1 trial, 10mg cohort ongoing By Investing.com - Investing.com Australia
PepGen reports favorable safety and splicing trends for 5 mg/kg cohort, on track for 10 mg/kg readout - TradingView — Track All Markets
[8-K] PepGen Inc. Reports Material Event - Stock Titan
Finanzdaten der Pepgen Inc-Aktie (PEPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):